CoChat

Evaluation of the safety, immunogenicity, and faecal shedding of novel oral polio vaccine type 2 in healthy newborn infants in Bangladesh: a randomised, controlled, phase 2 clinical trial

Open access

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Type 2 circulating vaccine-derived polioviruses (cVDPV2) from Sabin oral poliovirus vaccines (OPVs) are the leading cause of poliomyelitis. A novel type 2 OPV (nOPV2) has been developed to be more genetically stable with similar tolerability and immunogenicity to that of Sabin type 2 vaccines to mitigate the risk of cVDPV2. We aimed to assess these aspects of nOPV2 in poliovirus vaccine-naive newborn infants. METHODS: In this randomised, double-blind, controlled, phase 2 trial we enrolled newborn infants at the Matlab Health Research Centre, Chandpur, Bangladesh. We included infants who were healthy and were a single birth after at least 37 weeks' gestation. Infants were randomly assigned (2:1) to receive either two doses of nOPV2 or placebo, administered at age 0-3 days and at 4 weeks. Exclusion criteria included receipt of rotavirus or any other poliovirus vaccine, any infection or illness at the time of enrolment (vomiting, diarrhoea, or intolerance to liquids), diagnosis or suspicion of any immunodeficiency disorder in the infant or a close family member, or any contraindication for venipuncture. The primary safety outcome was safety and tolerability after one and two doses of nOPV2, given 4 weeks apart in poliovirus vaccine-naive newborn infants and the primary immunogenicity outcome was the seroconversion rate for neutralising antibodies against type 2 poliovirus, measured 28 days after the first and second vaccinations with nOPV2. Study staff recorded solicited and unsolicited adverse events after each dose during daily home visits for 7 days. Poliovirus neutralising antibody responses were measured in sera drawn at birth and at age 4 weeks and 8 weeks. This study is registered on ClinicalTrials.gov, NCT04693286. FINDINGS: Between Sept 21, 2020, and Aug 16, 2021, we screened 334 newborn infants, of whom three (<1%) were found to be ineligible and one (<1%) was withdrawn by the parents; the remaining 330 (99%) infants were assigned to receive nOPV2 (n=220 [67%]) or placebo (n=110 [33%]). nOPV2 was well tolerated; 154 (70%) of 220 newborn infants in the nOPV2 group and 78 (71%) of 110 in the placebo group had solicited adverse events, which were all mild or moderate in severity. Severe unsolicited adverse events in 11 (5%) vaccine recipients and five (5%) placebo recipients were considered unrelated to vaccination. 306 (93%) of 330 infants had seroprotective maternal antibodies against type 2 poliovirus at birth, decreasing to 58 (56%) of 104 in the placebo group at 8 weeks. In the nOPV2 group 196 (90%) of 217 infants seroconverted by week 8 after two doses, when 214 (99%) had seroprotective antibodies. INTERPRETATION: nOPV2 was well tolerated and immunogenic in newborn infants, with two doses, at birth and 4 weeks, resulting in almost 99% of infants having protective neutralising antibodies. FUNDING: Bill & Melinda Gates Foundation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(22)02397-2

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Trial profile nOPV2=novel oral poliovirus vaccine type 2.
Figure 1 Trial profile nOPV2=novel oral poliovirus vaccine type 2.CC BY · PubMed Central
Figure 2 Rates of solicited adverse events within 7 days of the first and second doses in the nOPV2 and placebo groups Severity shown only for placebo group as all adverse events in the nOPV2 group were reported as mild. nOPV2=novel oral poliovirus vaccine type 2.
Figure 2 Rates of solicited adverse events within 7 days of the first and second doses in the nOPV2 and placebo groups Severity shown only for placebo group as all adverse events in the nOPV2 group were reported as mild. nOPV2=novel oral poliovirus vaccine type 2.CC BY · PubMed Central
Figure 3 Neutralising antibody responses to two doses of nOPV2 or placebo Large panel shows GMTs against poliovirus type 2 and smaller panels show GMTs against poliovirus types 1 and 3 (appendix p 6). Error bars denote 95% CIs. GMT=geometric mean titre. nOPV2=novel oral poliovirus vaccine type 2.
Figure 3 Neutralising antibody responses to two doses of nOPV2 or placebo Large panel shows GMTs against poliovirus type 2 and smaller panels show GMTs against poliovirus types 1 and 3 (appendix p 6). Error bars denote 95% CIs. GMT=geometric mean titre. nOPV2=novel oral poliovirus vaccine type 2.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Research works printed but not linked: 1

  1. Bandyopadhyay, 2022, A novel tool to eradicate an ancient scourge: the nOPV2 story, Lancet Infect Dis

Cited by

See all 39

Metadata

Authors
Zaman, K., Bandyopadhyay, A. S., Hoque, M., Gast, C., Yunus, M., Jamil, K. M., Mainou, B. A., Konopka-Anstadt, J. L., Hendley, W. S., Vincent, A., Clemens, R., Clemens, S. A. C., Ross, A. G., Clemens, J. D., & Tritama, E.
Affiliations
  • Gates Foundation (US)
  • International Centre for Diarrhoeal Disease Research (BD)
  • Program for Appropriate Technology in Health (US)
  • Ministry of Health and Family Welfare (BD)
  • Centers for Disease Control and Prevention (US)
  • University of Oxford (GB)
  • Charles Sturt University (AU)
  • International Vaccine Institute (KR)
  • PT Bio Farma (Indonesia) (ID)
Corresponding author
Bandyopadhyay, Ananda S
Venue
The Lancet
Publisher
Elsevier BV
Published
2023-01
Volume
401
Issue
10371
Pages
131-139
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4310828209
Cited by
39
References
20
Citations by year
2026: 4 · 2025: 15 · 2024: 12 · 2023: 8
FWCI
6.09
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Charles Sturt University Research Output (CRO) (submittedVersion, cc-by)
  • Greater South Information System
Funders
  • Bill and Melinda Gates Foundation
  • Dartmouth College
  • International Centre for Diarrhoeal Disease Research, Bangladesh
  • Centers for Disease Control and Prevention
Topics
  • Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
  • Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
  • Social Sciences › Health › Vaccine Coverage and Hesitancy
Keywords
circulating vaccine-derived poliovirus type 2, vaccine immunogenicity, fecal shedding, neonates, neutralizing antibodies, vaccine adverse events, poliomyelitis prevention, Bangladesh, polio eradication, mother-to-child transmission
MeSH terms
Antibodies, Viral, Bangladesh, Child, Preschool, Double-Blind Method, Humans, Infant, Infant, Newborn, Poliomyelitis, Poliovirus Vaccine, Oral, Poliovirus, Antibodies, Neutralizing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluation of the safety, immunogenicity, and faecal shedding of novel oral polio vaccine type 2 in healthy newborn infants in Bangladesh: a randomised, controlled, phase 2 clinical trial. https://app.cochat.ai/papers/10.1016/s0140-6736(22)02397-2
The paper
Zaman, K., Bandyopadhyay, A. S., Hoque, M., Gast, C., Yunus, M., Jamil, K. M., Mainou, B. A., Konopka-Anstadt, J. L., Hendley, W. S., Vincent, A., Clemens, R., Clemens, S. A. C., Ross, A. G., Clemens, J. D., & Tritama, E. (2023). Evaluation of the safety, immunogenicity, and faecal shedding of novel oral polio vaccine type 2 in healthy newborn infants in Bangladesh: a randomised, controlled, phase 2 clinical trial. The Lancet. https://doi.org/10.1016/s0140-6736(22)02397-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.